What is the recommended Allegra dosage for adults and children. How should Allegra tablets, ODT, and oral suspension be taken. What are the potential drug interactions and side effects of Allegra.

Understanding Allegra: An Overview of Fexofenadine Hydrochloride

Allegra, known generically as fexofenadine hydrochloride, is a widely used antihistamine medication. It belongs to the class of drugs called antihistamines, which are primarily used to alleviate symptoms associated with allergies and chronic idiopathic urticaria (hives). Available in various formulations, including tablets, orally disintegrating tablets (ODT), and oral suspension, Allegra offers flexibility in dosing for different age groups and conditions.

Dosage Recommendations for Allegra Tablets

The dosage of Allegra tablets varies depending on the age group and the condition being treated. For adults and children 12 years and older, the recommended dose is either 60 mg twice daily or 180 mg once daily, taken with water. In patients with decreased renal function, a starting dose of 60 mg once daily is advised.

For children aged 6 to 11 years, the recommended dose is 30 mg twice daily with water. In pediatric patients with decreased renal function, a starting dose of 30 mg once daily is recommended.

How should Allegra tablets be taken?

• Take the tablet with water
• Can be taken with or without food
• Follow the prescribed dosing schedule
• Do not exceed the recommended dose

Allegra ODT: Dosage and Administration Guidelines

Allegra ODT (Orally Disintegrating Tablets) is specifically designed for children aged 6 to 11 years. The recommended dose is 30 mg twice daily. For pediatric patients with decreased renal function, a starting dose of 30 mg once daily is advised.

Key points for taking Allegra ODT:

• Place the tablet on the tongue to disintegrate
• Swallow with or without water
• Take on an empty stomach for best results
• Do not chew the tablet
• Keep the tablet in its original blister package until use

Allegra Oral Suspension: Dosing for Children

Allegra oral suspension offers a liquid formulation suitable for younger children. The dosage varies based on the child’s age and the condition being treated.

Dosage for Seasonal Allergic Rhinitis:

For children aged 2 to 11 years, the recommended dose is 30 mg twice daily. In cases of decreased renal function, a starting dose of 30 mg (5 mL) once daily is advised.

Dosage for Chronic Idiopathic Urticaria:

• Children 2 to 11 years: 30 mg (5 mL) twice daily
• Children 6 months to less than 2 years: 15 mg (2.5 mL) twice daily

For pediatric patients with decreased renal function, the recommended starting doses are 30 mg (5 mL) once daily for ages 2 to 11 years, and 15 mg (2.5 mL) once daily for ages 6 months to less than 2 years.

Remember to shake the bottle well before each use of the oral suspension.

Potential Drug Interactions with Allegra

Allegra can interact with various medications, potentially affecting its efficacy or increasing the risk of side effects. Understanding these interactions is crucial for safe and effective use of the medication.

How many known drug interactions does Allegra have?

According to the drug interaction checker, Allegra (fexofenadine) has 97 known drug interactions. These interactions are categorized as follows:

• 1 major interaction
• 84 moderate interactions
• 12 minor interactions

Additionally, there is 1 disease interaction and 1 alcohol/food interaction reported for Allegra.

Common medications that may interact with Allegra:

1. Albuterol
2. Amlodipine
3. Aspirin
4. Atorvastatin
5. Benadryl (diphenhydramine)
6. Cymbalta (duloxetine)
7. Fish Oil (omega-3 polyunsaturated fatty acids)
8. Flonase (fluticasone nasal)
9. Gabapentin
10. Hydrochlorothiazide

It’s important to consult with a healthcare provider or pharmacist about potential interactions before starting Allegra, especially if you’re taking other medications.

Side Effects and Precautions of Allegra

While Allegra is generally well-tolerated, like all medications, it can cause side effects in some individuals. Understanding these potential side effects and taking necessary precautions can help ensure safe and effective use of the medication.

What are the most common side effects of Allegra?

The most commonly reported side effects of Allegra include:

• Headache
• Drowsiness
• Nausea
• Dizziness
• Fatigue

These side effects are usually mild and often resolve on their own. However, if they persist or worsen, it’s important to consult a healthcare provider.

Precautions when taking Allegra:

1. Inform your doctor about all medications you’re taking, including over-the-counter drugs and supplements
2. Discuss any existing medical conditions, especially kidney problems
3. Avoid alcohol while taking Allegra, as it may increase the risk of side effects
4. Use caution when driving or operating machinery, as Allegra can cause drowsiness in some people
5. If you’re pregnant or breastfeeding, consult your doctor before taking Allegra

Comparing Allegra to Other Antihistamines

Allegra is one of several second-generation antihistamines available for treating allergies and hives. Understanding how it compares to other common antihistamines can help in making informed decisions about allergy treatment.

How does Allegra compare to Claritin for allergy relief?

Both Allegra (fexofenadine) and Claritin (loratadine) are effective second-generation antihistamines used for allergy relief. Here’s a brief comparison:

• Onset of action: Allegra typically starts working faster, within 1-3 hours, while Claritin may take up to 3 hours
• Duration: Allegra’s effects last about 12-24 hours, while Claritin’s effects can last up to 24 hours
• Drowsiness: Both are less likely to cause drowsiness compared to first-generation antihistamines, but Allegra may be slightly less sedating than Claritin
• Dosing: Allegra is often taken twice daily, while Claritin is usually taken once daily

The choice between Allegra and Claritin often depends on individual response and specific symptoms. Some people may find one more effective than the other for their particular allergies.

Can Allegra be taken with other antihistamines?

Generally, it’s not recommended to combine multiple antihistamines. Taking Allegra with other antihistamines like Zyrtec or Benadryl can increase the risk of side effects without providing additional benefits. However, in some cases, a healthcare provider might recommend a specific combination for short-term use.

If you’re considering taking Allegra with another antihistamine, it’s crucial to consult with a healthcare professional first. They can provide guidance based on your specific health needs and potential risks.

Allegra for Skin Conditions: Beyond Seasonal Allergies

While Allegra is widely known for its use in treating seasonal allergies, it’s also effective in managing certain skin conditions, particularly chronic idiopathic urticaria (hives). Understanding its application in dermatology can be beneficial for those suffering from skin-related allergic reactions.

What skin conditions can Allegra help with?

Allegra is primarily used for:

• Chronic Idiopathic Urticaria (CIU): Recurring hives of unknown cause
• Allergic skin reactions: Including itching and rashes caused by allergies
• Atopic dermatitis: May provide some relief from itching associated with this condition

It’s important to note that while Allegra can help manage symptoms of these skin conditions, it may not be suitable or effective for all types of skin problems. Always consult a dermatologist or healthcare provider for a proper diagnosis and treatment plan.

How does Allegra work to relieve itching?

Allegra works by blocking histamine, a substance in the body that causes allergy symptoms. In the case of skin conditions:

1. It reduces itching by preventing histamine from binding to its receptors in the skin
2. It helps decrease inflammation associated with allergic reactions
3. It can provide relief from hives by reducing their size and number

The effectiveness of Allegra for skin conditions can vary from person to person. Some individuals may find significant relief, while others may need additional or alternative treatments.

Allegra Dosage Guide – Drugs.com

Print

Save

Generic name: fexofenadine hydrochloride 30mg
Dosage forms: tablet, film coated, tablet, orally disintegrating, oral suspension
Drug class: Antihistamines

Medically reviewed by Drugs.com. Last updated on Mar 13, 2023.

ALLEGRA tablets

Seasonal Allergic Rhinitis and Chronic Idiopathic Urticaria

Adults and Children 12 Years and Older

The recommended dose of ALLEGRA tablets is 60 mg twice daily or 180 mg once daily with water. A dose of 60 mg once daily is recommended as the starting dose in patients with decreased renal function [see Clinical Pharmacology (12.3)].

Children 6 to 11 Years.

The recommended dose of ALLEGRA tablets is 30 mg twice daily with water. A dose of 30 mg once daily is recommended as the starting dose in pediatric patients with decreased renal function [see Clinical Pharmacology (12.3)].

ALLEGRA ODT

Seasonal Allergic Rhinitis and Chronic Idiopathic Urticaria

Children 6 to 11 Years:

ALLEGRA ODT is intended for use only in children 6 to 11 years of age. The recommended dose of ALLEGRA ODT is 30 mg twice daily. A dose of 30 mg once daily is recommended as the starting dose in pediatric patients with decreased renal function [see Clinical Pharmacology (12.3)].

ALLEGRA ODT is designed to disintegrate on the tongue, followed by swallowing with or without water. ALLEGRA ODT should be taken on an empty stomach. ALLEGRA ODT is not intended to be chewed.

ALLEGRA ODT should not be removed from the original blister package until the time of administration.

ALLEGRA oral suspension

Seasonal Allergic Rhinitis

Children 2 to 11 Years:

The recommended dose of ALLEGRA oral suspension is 30 mg twice daily. A dose of 30 mg (5 mL) once daily is recommended as the starting dose in pediatric patients with decreased renal function [see Clinical Pharmacology (12.3)].

Shake bottle well, before each use.

Chronic Idiopathic Urticaria

Children 6 Months to 11 Years:

The recommended dose of ALLEGRA oral suspension is 30 mg (5 mL) twice daily for patients 2 to 11 years of age and 15 mg (2. 5 mL) twice daily for patients 6 months to less than 2 years of age. For pediatric patients with decreased renal function, the recommended starting doses of ALLEGRA oral suspension are 30 mg (5 mL) once daily for patients 2 to 11 years of age and 15 mg (2.5 mL) once daily for patients 6 months to less than 2 years of age [see Clinical Pharmacology (12.3)].

Shake bottle well, before each use.

Frequently asked questions

• What are the most common skin conditions? (with photos)
• Allegra vs Claritin: Which is more effective for allergies?
• Can I take Allegra in the morning and Zyrtec in the evening?

More about Allegra (fexofenadine)

• Check interactions
• Compare alternatives
• Reviews (93)
• Drug images
• Side effects
• During pregnancy
• Support group
• Drug class: antihistamines
• Breastfeeding

Patient resources

• Drug Information
• Allegra (Advanced Reading)
• Allegra (Fexofenadine Oral Suspension)
• Allegra (Fexofenadine Tablets)

Other brands

Aller-Ease

Professional resources

• Prescribing Information

Other formulations

• Allegra-D 24 Hour

Related treatment guides

• Urticaria
• Allergic Rhinitis

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

Allegra Interactions Checker – Drugs.com

Print

Save

There are 97 drugs known to interact with
Allegra (fexofenadine), along with
1 disease interaction, and 1 alcohol/food interaction.

Of the total drug interactions,
1 is major, 84 are moderate, and 12 are minor.

Does Allegra interact with my other drugs?

Enter other medications to view a detailed report.

• View all 97 medications that may interact with Allegra
• View Allegra alcohol/food interactions (1)
• View Allegra disease interactions (1)

Most frequently checked interactions

View interaction reports for Allegra (fexofenadine) and the medicines listed below.

• Major
• Moderate
• Minor
• Unknown

• albuterol
• amlodipine
• aspirin
• atorvastatin
• Benadryl (diphenhydramine)
• Cymbalta (duloxetine)
• Fish Oil (omega-3 polyunsaturated fatty acids)
• Flonase (fluticasone nasal)
• gabapentin
• hydrochlorothiazide
• ibuprofen
• levothyroxine
• lisinopril
• losartan
• melatonin
• metformin
• montelukast
• multivitamin
• omeprazole
• prednisone
• Singulair (montelukast)
• Synthroid (levothyroxine)
• tramadol
• trazodone
• Tylenol (acetaminophen)
• Vitamin B12 (cyanocobalamin)
• Vitamin C (ascorbic acid)
• Vitamin D3 (cholecalciferol)
• Xanax (alprazolam)
• Zyrtec (cetirizine)

Allegra alcohol/food interactions

There is 1 alcohol/food interaction with Allegra (fexofenadine).

Allegra disease interactions

There is 1 disease interaction with Allegra (fexofenadine) which include:

• renal dysfunction

Report options

Loading…

QR code containing a link to this page

More about Allegra (fexofenadine)

• Allegra consumer information
• Compare alternatives
• Reviews (93)
• Drug images
• Side effects
• Dosage information
• During pregnancy
• Support group
• Drug class: antihistamines
• Breastfeeding

Related treatment guides

• Urticaria
• Allergic Rhinitis

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.

Major	Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate	Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor	Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown	No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

New possibilities in the treatment of chronic idiopathic urticaria

03/27/2015

Urticaria is one of the most common allergic diseases, affecting almost all age groups. According to statistics, 15-20% of the world’s population has at least one episode of urticaria during their lifetime. A significant variety of etiological factors and varying degrees of reactivity of the human body determine the variety of clinical forms of urticaria, the treatment of which requires a differentiated approach.

This disease is a peculiar, often allergic, reaction in response to various stimuli and may be the only manifestation of a pathological process or one of the signs of a disease. The acute form of urticaria often arises from exposure to external stimuli (insect bites), the influence of physical factors, in particular cold, sunlight, less often heat, with intolerance to a number of foods (meat and fish products, canned food, etc.), as well as when prescribing certain medicines. This is the so-called true, or exogenous, urticaria, which, depending on the causative factor, is divided into food, household, medicinal, pollen and other forms.

The causes of chronic endogenous form of urticaria are often foci of chronic infection in the human body, which are difficult to treat. This form of the disease is observed in metabolic disorders, diseases of the gastrointestinal tract and hepatobiliary system (cholecystitis, chronic hepatitis, dysbacteriosis, helminthic invasions giardiasis, opisthorchiasis), sometimes in patients with renal and hepatic insufficiency, diabetes mellitus, with blood diseases, malignant neoplasms (lymphogranulomatosis), cachexia, alcoholism and drug addiction, infectious diseases (for example, influenza), disorders of the female reproductive system, and pregnancy.

Nevertheless, despite the large list of nosological units against which urticaria develops, in more than 95% of cases, even with the most thorough examination, it is not possible to identify the etiological factor. Therefore, such forms are referred to as chronic idiopathic urticaria (CUI). It is more common in adults and is clinically characterized by edema, erythema, and wheals of unknown etiology that are permanently present, changing location, or occurring as relapses lasting more than 6 months.

Such persistent clinical symptoms do not pose a threat to the life of the patient, however, they can lead to disability and significantly impair the quality of life of patients, causing significant discomfort. They note sleep disturbances, daily activities, emotional disorders, the desire for social isolation, which is associated with cosmetic defects. The biggest concern is itchy skin.

The results of recent studies indicate that the effect of symptoms of CSI on the patient is comparable to those of coronary heart disease (J. Allergy Clin. Immunol, 1998).

At present, the pathogenesis of CI is not fully understood. Recent studies indicate that in a significant number of patients, urticaria is caused by autoimmune disorders, namely the formation of IgG autoantibodies directed against IgE or IgE receptors (Fce R1), resulting in activation of mast cells. The vasodilation and edema of the skin observed in CSI is due to the release of pro-inflammatory mediators, primarily histamine, from mast cells.

Based on the characteristics of the pathogenesis, the treatment of urticaria is currently aimed at eliminating the symptoms, that is, reducing the severity of itching, the number of blisters, and swelling of the skin. In most cases, antihistamines are considered the first choice in the treatment of patients with CCI due to their action on H ₁ -histamine receptors of postcapillary venules of the skin, thereby eliminating histamine-induced vasodilation and increased vascular permeability.

In addition, the drugs of this group have a reflex effect, preventing the development of erythema caused by histamine, and interact with H ₁ – histamine receptors of small branched unmyelinated C-nerve fibers of the skin, preventing the appearance of skin itching. Many antihistamines have pronounced anti-allergic and anti-inflammatory activity directly in the skin (F. Simons, N. Silver, X. Gu, K. Simons, 2001).

For a long time, second-generation antihistamines (terfenadine, astemizole, cetirizine, loratadine, ebastine, and some others) were considered preferable, which, in comparison with first-generation drugs, do not have a sedative effect in standard therapeutic doses (dose-dependent effect on the central nervous system) and have more specific blocking action on H ₁ are histamine receptors and do not cause anticholinergic effects. But later it was found that second-generation antihistamines are prodrugs, that is, when they enter the body, they are metabolized in the liver with the help of the CYP 3A4 isoenzyme of the cytochrome P450 system into active metabolites that directly block H ₁ -histamine receptors. Therefore, the appointment of drugs of this generation to patients with concomitant diseases of internal organs, in particular the liver, and metabolic disorders is undesirable due to the possibility of developing severe side effects. In addition, when co-administered with certain drugs (macrolide antibiotics, antifungal drugs), polymorphic ventricular tachycardia of the pirouette type (dorsades de pointes) may occur, combined with a prolongation of the QT interval, severe arrhythmia, which can be fatal in case of transition in ventricular fibrillation. Such life-threatening arrhythmias are caused by blockade of slow potassium channels of cardiomyocytes by second-generation antihistamines, which leads to repolarization of the ventricular myocardium. These severe complications prompted research to radically improve the profile of antihistamines. The optimal direction of such research was the creation of drugs based on pharmacologically active end metabolites (not subject to further transformations in the body) second generation drugs. Such drugs should, on the one hand, not have the negative properties of their predecessor, and on the other hand, not only retain its advantages, but also improve such pharmacological properties as the degree of affinity for receptors and the reproducibility of antihistamine action. Thus, the development of third-generation antihistamines was begun. The first drug of this generation was fexofenadine hydrochloride (Allegra/Telfast), which was registered in the United States on July 19.96 years after an unusually short clinical trial program of only about two years. It is an active carboxylated metabolite of terfenadine (D. Handley, A. Magnetti, A. Higgins, 1998).

Telfast, compared with antihistamines, has better pharmacological properties; after oral administration, it is rapidly absorbed, reaching a maximum plasma concentration after 1-3 hours. The duration of the effect is 24 hours. With repeated use, cumulation is not observed, since only 5% of the dose undergoes biotransformation in the liver, that is, the drug is practically not metabolized in the body, and tolerance does not develop. This ensures predictable plasma drug levels and low inter-individual variability. Due to the minimal amount of biotransformation in the body, fexofenadine can be prescribed to patients with liver diseases. In the elderly and patients with renal insufficiency, the content of fexofenadine in blood plasma can be twice its normal value, however, due to the high therapeutic Telfast index, side effects do not occur (D. Handley, A. Magnetti, A. Higgins, 1998).

Telfast does not have a significant effect on the slow potassium channels of cardiomyocytes, that is, it does not affect the electrophysiological properties of the myocardium. No drug-drug interactions of fexofenadine have been established. Its use in combination with ketoconazole or erythromycin is not accompanied by a statistically significant increase in the duration of the QT interval (C. Pratt et al., 1997).

In addition, fexofenadine does not penetrate the blood-brain barrier and, unlike drugs of the 1st and 2nd generations, does not have a dose-dependent effect on the central nervous system, does not have a negative effect on cognitive and psychomotor functions, which allows it to be prescribed to persons whose professional activities require increased attention (drivers, pilots, operators of various mechanisms).

In addition, the use of fexofenadine for the prevention and treatment of systemic allergic and local skin reactions (urticaria) has been shown to be advantageous due to the fact that the drug has significant organotropism and penetrates the skin to a much greater extent than diphenhydramine.

In subsequent years, data were obtained on the additional antiallergic properties of fexofenadine, the spectrum of which turned out to be very wide. In particular, at concentrations comparable to blood concentrations, when taken orally at a therapeutic dose of Telfast, fexofenadine inhibits the secretion of histamine from mast cells, blocks the increase in the permeability of epithelial cells and the release of interleukin-8, granulocyte macrophage colony-stimulating factor and the soluble form of the intercellular adhesion molecule (ICAM-1 ) caused by activated eosinophils. Fexofenadine directly affects eosinophils, inhibiting their chemotaxis and adhesion to epithelial cells.

The data obtained suggest the effectiveness of Telfast in patients with CCI. In order to study the efficacy and safety of fexofenadine in patients with CCI, a multicenter, double-blind, placebo-controlled study was conducted in France, Great Britain and Germany in 1998 (E. Paul, J. Berth-Jones, J-P. Ortonne, M. Stern, 1998). Randomized patients were given fexofenadine at doses of 60, 120, 180, and 240 mg/day, while the control group received placebo. Primary efficacy criteria included the dynamics of the average total index of symptoms (the sum of the indices of itching and rash blisters), secondary various assessments of the therapeutic effect by patients and doctors. Therapy with fexofenadine at doses of 180 and 240 mg resulted in a significant reduction in the total symptom index compared with placebo. In both groups, the drug caused a significant improvement in the pruritus index, compared with placebo, since H 9 blockers0019 1 -histamine receptors eliminate itching more effectively than urticaria. At the same time, a significant decrease in the number of rashes (blisters) was observed only when using the drug at a dose of 180 mg. There was also a significant improvement in sleep and daily activity of patients in the fexofenadine groups, indicating that the drug can improve the quality of life of patients with CCI. During the 6-week study, fexofenadine was well tolerated, the frequency of adverse effects in the fexofenadine groups was comparable or slightly lower than in the placebo group (25 and 33%, respectively). It should be noted that none of the patients treated with fexofenadine noted the appearance of drowsiness during treatment. The use of the drug was not accompanied by electrocardiographic changes.

Study results indicate that fexofenadine 180 and 240 mg once daily is an effective, safe and well tolerated treatment for CUC, with a recommended dose of 180 mg once daily.

Thus, Telfast is the drug of choice in the treatment of not only allergic rhinitis, but also chronic idiopathic urticaria. Its appointment can significantly reduce the severity of the symptoms of the disease, as well as improve the quality of life of such patients.

• Number:
• No. 71 May – General therapeutic number

06/21/2023

Therapy and family medicine For the sake of the Reader – Lyudin, Vcheny, Teacher and Doctor

April 2023 20 years passed, as Lyubov Trokhimivna Mala came from life – a person of great letters, a wise teacher, a founder of the Academy of Medical Sciences (AMS) of Ukraine, a woman of international knowledge, as she went through folding paths of war, kaval er rich orders, academician of the Academy of Medical Sciences. . ..

06/21/2023

PsychiatryEarly diagnosis of stress-associated neurotic disorders

Neurotic disorders associated with stress are considered to be the widest range of common mental disorders. In the rest of the hour, the number of ailments grows rapidly, which is connected with social transformations, mindful of the total onslaught of scientific and technological progress. The most intense psychosocial stress, which is poured into all levels of modern Ukrainian society, is war. For the tribute of the All-World Organization for the Protection of Health, 16.2% of the population is suffering through the legacy of war, and 12.5% ​​of their relatives are traumatized by war. …

06/21/2023

Obstetrics/Gynecology Dienogest and yogo generic drug against endometriosis

dilyankah, like from the ovaries, uterine trumpets that empty heart. In Ukraine (as in the whole world), this pathology affects ≈10% of women, and the greatest prevalence (30-50%) is observed among patients with reproductive disorders. In the structure of gynecological disease, endometriosis occurs on the 3rd month; its breadth does not tend to decrease. Vin є ’meaningful social tender, you can do it, so I am aimed, so it is prostrate, it is hard to make a hackist Zhitty Zhitty (Solimana. M. et al., 2017; Ramin-Wright A. et al., 2018) … .

06/21/2023

Therapy and family medicine New potential anticoagulants based on inhibitors of pharyngeal factor XIa

court code. However, for some pathological states, the process can be disrupted, and the very occlusion of the judge (removal of obstruction through the thrombus), which means thromboembolism. Thrombosis is caused both in arterial and venous vessels. It treats the development of heart attack, ischemic stroke and deep vein thrombosis. Thromboembolic disease is a serious medical problem and the fourth cause of skin death in the world….

Allegra 120mg tab.p.p.o. No. 10 with free home delivery from VkusVill

VkusVill

Oblong, biconvex film-coated tablets of light pink color, engraved “012” on one side, stylized “e” on the other.

Allegra 120mg tab.b.p.o. №10 / Pharmacy

Waiting for appraisal

Vkusvill

860 rub/piece 860.00 860.00

from the partner “SUPERAPTEKA”

Features of the category “Pharmacy” Online payment only

We deliver medical products of partners. Can be ordered separately, can be together with the products. Delivery times are the same.

Pharmaceutical partner licenses

Description

Oblong, biconvex light pink film-coated tablets, engraved “012” on one side and stylized “e” on the other side.